1 March 2022 - The March 2022 issue of the New Zealand Pharmaceutical Schedule is now available and in effect.

There are a few new listings of note this month:

• Adalimumab (Amgevita) - new biosimilar medicine
• Remdesivir (Veklury) - new indication (effective 28 February 2022)'

Read New Zealand Pharmaceutical Schedule update